Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$291.48 -0.2%	$315.08	$261.85 ▼ $495.55	$38.99B	0.31	1.14 million shs	975,712 shs
GILD Gilead Sciences	$133.05 -1.4%	$138.45	$97.86 ▼ $157.29	$167.54B	0.31	6.07 million shs	6.67 million shs
IBB iShares Biotechnology ETF	$172.65 +0.2%	$169.33	$116.49 ▼ $179.64	$8.19B	0.73	1.37 million shs	775,056 shs
REGN Regeneron Pharmaceuticals	$719.88 -0.5%	$747.55	$476.49 ▼ $821.11	$76.48B	0.3	780,847 shs	879,251 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-0.19%	-3.80%	-12.47%	-5.51%	+9.23%
GILD Gilead Sciences	-1.40%	-2.38%	-4.30%	-12.36%	+31.17%
IBB iShares Biotechnology ETF	+0.21%	-0.70%	+0.27%	+1.18%	+44.44%
REGN Regeneron Pharmaceuticals	-0.49%	-0.16%	-3.56%	-8.14%	+25.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$291.48 -0.2%	$315.08	$261.85 ▼ $495.55	$38.99B	0.31	1.14 million shs	975,712 shs
GILD Gilead Sciences	$133.05 -1.4%	$138.45	$97.86 ▼ $157.29	$167.54B	0.31	6.07 million shs	6.67 million shs
IBB iShares Biotechnology ETF	$172.65 +0.2%	$169.33	$116.49 ▼ $179.64	$8.19B	0.73	1.37 million shs	775,056 shs
REGN Regeneron Pharmaceuticals	$719.88 -0.5%	$747.55	$476.49 ▼ $821.11	$76.48B	0.3	780,847 shs	879,251 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-0.19%	-3.80%	-12.47%	-5.51%	+9.23%
GILD Gilead Sciences	-1.40%	-2.38%	-4.30%	-12.36%	+31.17%
IBB iShares Biotechnology ETF	+0.21%	-0.70%	+0.27%	+1.18%	+44.44%
REGN Regeneron Pharmaceuticals	-0.49%	-0.16%	-3.56%	-8.14%	+25.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.81	Moderate Buy	$471.96	61.92% Upside
GILD Gilead Sciences	2.86	Moderate Buy	$157.04	18.03% Upside
IBB iShares Biotechnology ETF	2.74	Moderate Buy	$172.65	N/A
REGN Regeneron Pharmaceuticals	2.77	Moderate Buy	$826.59	14.82% Upside

Current Analyst Ratings Breakdown

Latest IBB, ALNY, GILD, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/11/2026	GILD Gilead Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
5/11/2026	GILD Gilead Sciences	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$170.00 ➝ $167.00
5/8/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$175.00 ➝ $168.00
5/8/2026	GILD Gilead Sciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target		$148.00 ➝ $146.00
5/8/2026	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00 ➝ $157.00
5/8/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$123.00 ➝ $122.00
5/5/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$510.00
5/4/2026	ALNY Alnylam Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
5/1/2026	ALNY Alnylam Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$450.00 ➝ $445.00
5/1/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$376.00 ➝ $377.00
5/1/2026	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$975.00 ➝ $995.00

(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	10.48	$2.79 per share	104.44	$8.05 per share	36.21
GILD Gilead Sciences	$29.44B	5.61	$10.32 per share	12.89	$18.87 per share	7.05
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$14.34B	5.31	$41.78 per share	17.23	$297.23 per share	2.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$3.66	79.64	28.38	N/A	11.72%	85.76%	10.32%	7/30/2026 (Estimated)
GILD Gilead Sciences	$8.51B	$7.34	18.13	13.70	N/A	30.99%	48.19%	18.28%	N/A
IBB iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$41.04	17.54	17.34	1.60	29.65%	13.16%	10.17%	7/30/2026 (Estimated)

Latest IBB, ALNY, GILD, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
4/30/2026	Q1 2026	ALNY Alnylam Pharmaceuticals	$0.8720	$1.99	+$1.1180	$1.51	$1.12 billion	$1.17 billion
4/29/2026	Q1 2026	REGN Regeneron Pharmaceuticals	$8.91	$9.47	+$0.56	$6.75	$3.48 billion	$3.61 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.47%	+3.04%	44.69%	10 Years
IBB iShares Biotechnology ETF	$0.39	0.23%	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.52%	N/A	9.16%	N/A

Latest IBB, ALNY, GILD, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.45%	6/15/2026	6/15/2026	6/29/2026
4/29/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.55%	5/20/2026	5/20/2026	6/4/2026
3/16/2026	IBB iShares Biotechnology ETF	Quarterly	$0.1218	0.29%	3/17/2026	3/17/2026	3/20/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
GILD Gilead Sciences	0.89	1.97	1.77
IBB iShares Biotechnology ETF	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	0.06	3.57	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
GILD Gilead Sciences	83.67%
IBB iShares Biotechnology ETF	62.45%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
GILD Gilead Sciences	0.30%
IBB iShares Biotechnology ETF	N/A
REGN Regeneron Pharmaceuticals	6.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.51 million	132.37 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
IBB iShares Biotechnology ETF	N/A	47.55 million	N/A	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable

IBB, ALNY, GILD, and REGN Headlines

Recent News About These Companies

Freemont Management S.A. Takes $5.09 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

2 hours ago | marketbeat.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

May 13 at 7:43 AM | marketbeat.com

Swiss Life Asset Management Ltd Has $8.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

May 13 at 5:42 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 12 at 4:11 PM | seekingalpha.com

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

May 12 at 1:28 PM | finance.yahoo.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Securian Asset Management Inc.

May 12 at 5:58 AM | marketbeat.com

Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?

May 11 at 12:52 AM | finance.yahoo.com

Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?

May 11 at 8:31 PM | insidermonkey.com

Peak Wealth Management LLC Invests $4.02 Million in Regeneron Pharmaceuticals, Inc. $REGN

May 11 at 6:42 AM | marketbeat.com

Osprey Private Wealth LLC Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

May 10, 2026 | marketbeat.com

Regeneron’s Otarmeni Win Links Gene Therapy Ambition With ESG Commitments

May 9, 2026 | finance.yahoo.com

Generali Asset Management SPA SGR Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

May 9, 2026 | marketbeat.com

F m Investments LLC Has $17.61 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

May 9, 2026 | marketbeat.com

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

May 8, 2026 | finance.yahoo.com

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

May 8, 2026 | globenewswire.com

Is This Biotech Stock a Buy After a Groundbreaking Approval?

May 8, 2026 | fool.com

Lilly and Regeneron Advance Obesity Combo Bet as Key Tirzepatide Trial Reaches Completion

May 7, 2026 | tipranks.com

Trump’s Affordability Push Stalls Ahead of Midterm Elections

May 7, 2026 | finance.yahoo.com

Lmcg Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN

May 7, 2026 | marketbeat.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by K.J. Harrison & Partners Inc

May 7, 2026 | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

May 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IBB, ALNY, GILD, and REGN Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$291.48 -0.55 (-0.19%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$291.56 +0.08 (+0.03%)

As of 05:10 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences NASDAQ:GILD

$133.05 -1.89 (-1.40%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$132.88 -0.17 (-0.12%)

As of 06:40 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

iShares Biotechnology ETF NASDAQ:IBB

$172.65 +0.37 (+0.21%)

As of 05/13/2026 04:00 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Regeneron Pharmaceuticals NASDAQ:REGN

$719.88 -3.53 (-0.49%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$721.12 +1.24 (+0.17%)

As of 06:32 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBB, ALNY, GILD, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBB, ALNY, GILD, and REGN Earnings

Compare Dividends

Latest IBB, ALNY, GILD, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBB, ALNY, GILD, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IBB, ALNY, GILD, and REGN Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Gilead Sciences NASDAQ:GILD

iShares Biotechnology ETF NASDAQ:IBB

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools